Article 3: On cough syrups, a long overdue prescription
Why in news: The Centre has removed cough syrups from Schedule K of the Drugs Rules, 1945, ending over-the-counter sales following multiple deaths linked to contaminated syrups and concerns over drug safety.
Key Details
- Cough syrups removed from Schedule K of the Drugs Rules, 1945.
- Ends over-the-counter sale; prescription now mandatory.
- Triggered by deaths of children in MP, Rajasthan, and Jammu.
- India-made syrups linked to 140+ child deaths abroad since 2022.
- Diethylene Glycol (DEG) contamination found in Coldrif syrup.
- Exemptions encouraged self-medication and weak accountability.
- Need for stronger quality control, inspections, and rural healthcare access.
Regulatory Failure and Delayed Reform
- The Central Government has removed cough syrups from Schedule K of the Drugs Rules, 1945.
- This decision addresses a long-standing weakness in drug regulation.
- The move comes after several tragic incidents linked to contaminated cough syrups.
- It reflects a delayed but necessary response to repeated safety concerns.
Repeated Tragedies and Loss of Lives
- In October 2025, more than 20 children died in Madhya Pradesh and Rajasthan after consuming locally purchased cough syrups.
- Similar deaths were reported in Jammu between December 2019 and January 2020.
- India-manufactured cough syrups have also been linked to the deaths of over 140 children in Africa and Central Asia since 2022.
- These incidents exposed serious gaps in quality control and regulatory oversight.
Regulatory Loopholes in Cough Syrup Sales
- Certain cough syrups were exempted under Entry 13 of Schedule K.
- These exemptions allowed sales through channels with weaker monitoring than licensed pharmacies.
- The system encouraged self-medication and reduced prescription compliance.
- Accountability gaps persisted across manufacturers, distributors, and retail sellers.
Impact on Rural and Vulnerable Communities
- The exemptions particularly affected villages with populations below 1,000, where sales were permitted.
- Vulnerable communities faced greater risks due to limited healthcare access.
- In Madhya Pradesh, the cough syrup Coldrif was found to contain excessive levels of diethylene glycol (DEG), a toxic substance.
- Weak regulatory monitoring increased public health risks in rural areas.
Significance of the New Prescription Requirement
- All syrup-based medicines, including opioid-containing cough syrups such as those with codeine, now require a medical prescription.
- Over-the-counter (OTC) sales of these medicines have been restricted.
- The reform aims to improve patient safety and reduce misuse and abuse.
- It also strengthens control over the distribution and consumption of cough syrups.
Challenges and the Way Forward
- A prescription mandate alone will not solve all problems.
- Weak Centre–State coordination continues to affect drug regulation.
- Stronger quality inspections, enforcement mechanisms, and adverse-event reporting systems are needed.
- Greater investment in rural healthcare infrastructure is essential to reduce dependence on unlicensed vendors.
- India must foster a patient-centric regulatory culture that prioritises preventive safety measures over crisis-driven responses.
Conclusion
The decision marks an important step toward strengthening drug safety and patient protection. However, regulatory reform must extend beyond prescription requirements to include stronger quality checks, better Centre–State coordination, transparent reporting systems, and improved rural healthcare access. A robust and preventive regulatory framework is essential to restore public trust and prevent future tragedies caused by unsafe pharmaceutical products.
Descriptive question:
Q. "Recent incidents involving contaminated cough syrups have exposed critical weaknesses in India's pharmaceutical regulatory framework. Examine the challenges in drug regulation and suggest measures to strengthen patient safety." (15 Marks, 250 Words)
Source: The Indian Express